Providers/Grant Support
This activity is supported by an independent educational grant from Melinta Therapeutics.
Credits Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
- Nurses — 1.5 Nursing Contact Hours
- Pharmacists — 1.5 contact hours (0.15 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This initiative is intended for infectious diseases physicians, critical care physicians, hospitalists, hematologists/oncologists, surgeons, pathologists/clinical microbiologists, pharmacists, pediatric infectious disease specialists, transplant specialists, advanced practice providers, and nurses and other healthcare professionals responsible for the management of invasive fungal infections.
Program Overview
Invasive candidiasis is the most common invasive fungal infection and remains associated with substantial morbidity and mortality. Despite new antifungal options, gaps persist in optimal initial therapy selection, source control, and transitions of care, particularly when patients have chronic or disseminated candidiasis. This activity, based on a live Town Hall held on September 29, 2025, uses real-world case studies and a patient perspective to highlight practical strategies for improving clinical decision-making and patient-centered outcomes for invasive candidiasis.
Learning Objectives
Upon completing this activity, the participant should be better able to:
- Define patient and local epidemiologic factors that influence initial therapy for invasive candidiasis.
- Select appropriate antifungal therapy for front-line care and step-down management.
- Evaluate factors affecting outcomes during transitions from hospital to outpatient settings.
- Promote adherence and positive patient-centered outcomes in chronic invasive candidiasis.
Faculty
Peter G. Pappas, MD, FACP
Chairperson
Professor of Medicine Chair, Scientific Committee MSGERC
University of Alabama at Birmingham
Birmingham, Alabama
Dr Peter G. Pappas is Professor of Medicine in the Division of Infectious Diseases at the University of Alabama in Birmingham (UAB). Dr Pappas was the inaugural William E. Dismukes Professor of Medicine and the first Tinsley Harrison Clinical Scholar at UAB. He attended medical school at the UAB, graduating in 1978. He completed his residency in internal medicine, chief medical residency, and infectious diseases fellowship at the University of Washington in Seattle. Following completion of his fellowship, he was on the clinical faculty at the University of North Carolina School of Medicine in Chapel Hill, NC, through its affiliated hospital in Wilmington, NC. In 1988, he joined the faculty at the University of Alabama in Birmingham School of Medicine, with a focus on HIV and transplant-associated opportunistic infections, especially the invasive mycoses. His main areas of interest over the last three decades have included the development of new therapies for fungal infections, fungal diagnostics, and understanding the epidemiology of candidiasis, the endemic mycoses, and cryptococcosis. He has performed numerous clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis through his involvement with the NIAID Mycoses Study Group and the Mycosis Study Group Education and Research Consortium (MSGERC).
Dr Pappas is Chair of the Scientific Committee of the MSGERC. He is also the principal investigator for the MSG Central Unit at the University of Alabama in Birmingham, from which most MSG clinical trials are administered. He has served as principal investigator of a national network of transplant centers, TRANSNET, in conjunction with the US Centers for Disease Control and Prevention and a consortium of industry co-sponsors to provide important epidemiologic and treatment information to transplant recipients who develop proven and probable invasive fungal infections. More recently, he served as co-principal investigator of the Organ Transplant Infection Detection and Prevention Program (OTIP), a collaborative multicenter group funded by the CDC.
Sarah Hammond, MD
Director of Hematology/Oncology Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Sarah Hammond, MD, is an assistant professor of medicine at Harvard Medical School. She is part of the clinical faculty in the Infectious Diseases and Hematology/Oncology Divisions at Massachusetts General Hospital, where she is the Director of Hematology/Oncology Infectious Diseases. Her clinical research focuses on the prevention and treatment of invasive fungal infections in high-risk cancer and transplant populations and in infectious complications of novel immunomodulatory therapies in patients with hematologic malignancy.
Michael Mansour, MD, PhD
Associate Professor of Medicine
Clinical Investigator
Massachusetts General Hospital
Boston, Massachusetts
Michael Mansour, MD, PhD, is an associate professor of medicine and a clinical investigator at Massachusetts General Hospital in Boston, Massachusetts. His research interest focuses on the critical molecular mechanisms responsible for host immune responses to life-threatening pathogens. His laboratory focuses on neutrophils and the role of fungal carbohydrates in innate immunity. His research involves predictive modeling to assess the risk of fungal infection in susceptible patients. This work is directed to development of cellular therapies for infectious diseases as well as improved vaccine strategies.
Stephanie Dunn
Patient Living with Chronic Invasive Candidiasis
Muscle Shoals, Alabama
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium (MSGERC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-25-374-H01-P)
Type of Activity: Application
Disclosures of Conflict of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty Disclosures
Peter G. Pappas, MD, FACP
INDEPENDENT CONTRACTOR (DATA REVIEW): F2G
INVESTIGATOR: Astellas, IMMY
CONSULTANT, ADVISOR: Melinta Therapeutics, Basilea Pharmaceutica
Sarah Hammond, MD
INVESTIGATOR: Cidara/Mundipharma, F2G, Scynexis, and GSK
CONSULTANT: Melinta, Pfizer, Roche, Seres Therapeutics, Takeda, and Treeline Biosciences
Michael Mansour, MD, PhD
INVESTIGATOR: Karius, ThermoFisher, Genentech, Roche, and CytoVale
CONSULTANT: Roche and Vericel
WRITER: UpToDate
Managers and Planning Committee Disclosures
The Terranova planners (Lisa A. Tushla, PhD, H[ASCP], and Marisa F. Baldassano, MD) as well as the Partners planners have no relevant financial relationship(s) to disclose with ineligible companies.
Instructions for Participation and Credit
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 11/26/2025 through 11/25/2026:
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity quiz(zes)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-assessment, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily reflect the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discuss suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review to applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For further information, contact Tom Davis by email ([email protected]).
For additional information about the accreditation of this activity, visit https://partnersed.com.